Cisplatin-Based Therapy for the Treatment of Elderly Patients with Non-Small-Cell Lung Cancer: a Retrospective Analysis of a Single Institution

Basit Öğe Kaydı
dc.contributor.authorInal, Ali
dc.contributor.authorKaplan, M. Ali
dc.contributor.authorKucukoner, Mehmet
dc.contributor.authorUrakci, Zuhat
dc.contributor.authorKarakus, Abdullah
dc.contributor.authorIsikdogan, Abdurrahman
dc.date.accessioned2024-04-24T17:28:15Z
dc.date.available2024-04-24T17:28:15Z
dc.date.issued2012
dc.departmentDicle Üniversitesien_US
dc.description.abstractBackground: In spite of the fact that platinum-based doublets are considered the standard therapy for patients with advanced non-small-cell lung cancer (NSCLC), no elderly-specific platinum based prospective phase III regimen has been explored. The aim of this retrospective singlecenter study was to evaluate the efficacy and side effects of cisplatin-based therapy specifically for the elderly. Methods: Patients receiving platinum-based treatment were divided into three groups. In the first group (GC), Gemcitabine was administrated at 1000 mg/m(2) on days 1, 8 and cisplatin was added at 75 mg/m(2) on day 1. In the second group (DC), 75 mg/m(2) docetaxel and cisplatin were administered on day 1. The third group (PC) received 175 mg of paclitaxel and 75 mg of cisplatin on day 1. These treatments were repeated every three weeks. Result: GC arm had 36, the DC arm 42 and the PC arm 29 patients. Grade III-IV thrombocytopenia was higher in the GC arm (21.2% received GC, 2.8% received DC, and 3.8% received PC), while sensory neuropathy was lower in patients with GC arm (3.0%, 22.2%, and 23.1% received GC, DC and PC, respectively). There were no statistically significant difference in the response rates among the three groups (p>0.05). The median Progression-free survival (PFS) was 5.0 months and the median Overall survival (OS) in each group was 7.1, 7.4 and 7.1 months, respectively (p>0.05). Conclusion: The response rate, median PFS and OS were similar among the three treatment arms. Grade III-IV thrombocytopenia was higher in the GC arm, while the GC regimen was more favorable than the other cisplatin-based treatmetns with regard to sensory neuropathy.en_US
dc.identifier.doi10.7314/APJCP.2012.13.5.1837
dc.identifier.endpage1840en_US
dc.identifier.issn1513-7368
dc.identifier.issue5en_US
dc.identifier.pmid22901132
dc.identifier.startpage1837en_US
dc.identifier.urihttps://doi.org/10.7314/APJCP.2012.13.5.1837
dc.identifier.urihttps://hdl.handle.net/11468/20379
dc.identifier.volume13en_US
dc.identifier.wosWOS:000309470100024
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherAsian Pacific Organization Cancer Preventionen_US
dc.relation.ispartofAsian Pacific Journal of Cancer Prevention
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAdvanced Lung Canceren_US
dc.subjectElderly Patientsen_US
dc.subjectFirst Line Chemotherapyen_US
dc.subjectCisplatin Based Therapyen_US
dc.titleCisplatin-Based Therapy for the Treatment of Elderly Patients with Non-Small-Cell Lung Cancer: a Retrospective Analysis of a Single Institutionen_US
dc.titleCisplatin-Based Therapy for the Treatment of Elderly Patients with Non-Small-Cell Lung Cancer: a Retrospective Analysis of a Single Institution
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu